deferiprone (ferriprox) Report issue

Small molecule Orphan Drug FDA Approved FDA Accelerated Approval FDA

Active Ingredient History

  • Now
Deferiprone (trade name Ferriprox) is an iron chelator indicated for the treatment of patients with transfusional iron overload due to thalassemia syndromes when current chelation therapy is inadequate. Deferiprone is an orally bioavailable bidentate ligand with iron chelating activity. Deferiprone binds to iron in a 3:1 (ligand:iron) molar ratio. By binding to iron, deferiprone is able to remove excess iron from the body. All the adverse effects of deferiprone are considered reversible, controllable and manageable. These include agranulocytosis with frequency of about 0.6%, neutropenia 6%, musculoskeletal and joint pains 15%, gastrointestinal complains 6% and zinc deficiency 1%.   NCATS

  • Mol. Mass: 139.1519
  • ALogP: 0.4
  • ChEMBL Molecule:
More Chemistry
  • Mechanism of Action:
  • Multi-specific: Missing data
  • Black Box: Yes
  • Availability: Prescription Only
  • Delivery Methods: Oral
  • Pro Drug: No

Drug Pricing (per unit)


$2.9867 - $149.3383

United States

$8.8177 - $128.5750
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

1,2-dimethyl-3-hydroxy-4-pyridinone | 1,2-dimethyl-3-hydroxypyrid-4-one | 1,2-dimethyl-3-hydroxypyridin-4-one | 3-hydroxy-1,2-dimethyl-4(1h)-pyridone | 3-hydroxy-1,2-dimethyl-4-pyridinone | apo-066 | apo-66 | cp20 | crmd-001 | deferione | deferipron | deferiprona | deferiprone | défériprone | deferiproni | deferipronum | deferypron | defriprone | dimethylhydroxypyridone | dmohpo | dn-180-01-af | ferriprox | hdmpp cpd | hdpp | l1 | l1 oral chelate | pl1 | pl-1


Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue